CME Information

Accreditation

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Target Audience

Surgical oncologists and other health care professionals practicing in the areas of medical, surgical, thoracic, and gynecologic oncology, and gastroenterology, as well as researchers involved in the field of hyperthermia and regionally applied biologic therapies.

Overall Educational Objectives

Upon completion of the activity, learners from several disciplines should be able to:

Summarize the most recent advances in cancer therapy that are primarily of a regional approach.
Describe the current role of regional therapy in the management of metastatic cancer.
Implement the latest regional therapies in surgical oncology into practice.
Distinguish areas of active research around regional therapy and identify ongoing clinical trials and clinical trials in development.

Designation

The Society of Surgical Oncology (SSO) designates this live activity for a maximum of 17.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

The primary purpose of 2025 Advanced Cancer Therapies is educational. Information, as well as technologies, products and/or services discussed, are intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and the SSO disclaims any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.